Short- and immediate-term outcomes after sugammadex versus neostigmine in patients with severe chronic kidney disease: A retrospective cohort study

Sugammadex was not associated with a significantly increased risk of pulmonary, cardiovascular, or mortality outcomes compared with neostigmine in patients with severe CKD having elective gastrointestinal surgery. Given the potential residual confounding by unmeasured factors such as surgical complexity, randomized controlled trials are needed to confirm these findings.